Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Thromboembolism

• Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
• RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
• Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
• Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
• Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
• VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
• Supplemental Oxygen in Pulmonary Embolism (SO-PE)
• Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial
• Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
• SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
• THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
• DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
• Venous Thromboembolism Prevention in Outpatients With Glioma
• Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets: the BAT-VTE
• TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
• A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
• Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
• Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
• Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
• A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With No
• Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
• The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19
• A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
• Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
• The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
• Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
• A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
• A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
• SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
• Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
• Thromboprophylaxis in Oesophageal Cancer Patients
• Optimization of Postpartum Thromboprophylaxis
• THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
• Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
• Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
• Use of Tranexamic Acid in Reduction Mammoplasty
• Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
• A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
• Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
• Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
• Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
• Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
• Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")
• Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
• Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
• Safety of Fondaparinux as Post Partum Thromboprophylaxis
• A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
• Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
• Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
• Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
• Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
• Statins for Venous Event Reduction in Patients With Venous Thromboembolism
• Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
• Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
• Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
• Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
• Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
• Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
• Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
• Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
• A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers
• Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
• A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)
• Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
• VTE Prevention Following Total Hip and Knee Arthroplasty
• Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
• Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
• Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
• Risk Stratification Procedure for Thromboembolism Prophylaxis
• PET Fibrin Imaging of DVT and PE
• Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
• Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event
• Screening for Cancer in Patients With Thromboembolic Disease
• Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease
• A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers
• Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
• Selective Thromboembolism Prophylaxis After Arthroplasty
• Apixaban for Extended Anticoagulation (APIDULCIS)
• Low INR to Minimize Bleeding With Mechanical Valves Trial
• Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
• PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
• Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery
• Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin
• Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
• Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring
• Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy
• Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
• REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
• Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
• FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
• Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
• Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology
• A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
• Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
• Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
• Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
• The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
• Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
• A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
• The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
• Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
• Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
• Timing of VTE Prophylaxis in TBI
• Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.
• Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
• Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
• Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty
• PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
• Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
• Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
• Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
• Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)
• Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
• Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
• Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
• A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
• Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
• STAT-STatin and Aspirin in Trauma
• Rivaroxaban in Mechanical Valves: RMV Study
• Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism
• anti10a Levels in Women Treated With LMWH in the Postpartum Period
• ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
• Direct Oral Anticoagulants and Venous Thromboembolism
• PK of Rivaroxaban in Bariatric Patients - Extension
• RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
• Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients
• A Different Approach to Preventing Thrombosis
• Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
• A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
• Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
• Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
• Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients
• StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study
• Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
• Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
• Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
• Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
• Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
• A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
• Tecarfarin Anti-Coagulation Trial (TACT)
• Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection
• Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose
• : Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
• Apixaban for the Acute Treatment of Venous Thromboembolism in Children
• Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
• Rivaroxaban in Bariatric Surgery
• Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
• Enoxaparin Metabolism in Reconstructive Surgery Patients
• Aspirin and Enoxaparin for VTE in Trauma
• The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
• The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT
• Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
• Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
• Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
• Statin Use in Patients With Acute VTE
• Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
• EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
• Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
• Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
• Prophylaxis of Venous Thromboembolism After Bariatric Surgery
• Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
• EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
• Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
• START-Register: Survey on Anticoagulated Patients Register
• Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
• Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
• Cancer Associated Thrombosis and Isoquercetin (CATIQ)
• Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery
• BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery
• Pharmacokinetics of Enoxaparin in Intensive Care Patients
• Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation
• Cancer Venous Thromboembolism (VTE)
• Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
• Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
• Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
• Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
• Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
• Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer
• Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
• Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
• A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery
• Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
• Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
• Weight Based Enoxaparin in Trauma Patients
• Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
• Eliquis Regulatory Post Marketing Surveillance (rPMS)
• Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
• Anticoagulation Length in Cancer Associated Thrombosis
• Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
• Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
• Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
• Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
• Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty
• Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies
• Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
• Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
• Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
• Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy
• Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
• Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
• Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
• PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients
• Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
• Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
• Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)
• Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
• Follow on Study From RE-ALIGN
• Fondaparinux in Critically Ill Patients With Renal Failure
• Effect of Tumescent Lidocaine on Platelet Function
• WEUSKOP5410: Observational Study in ENABLE Clinical Trials
• Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin
• Optimal Prophylactic Method of Venous Thromboembolism (VTE)
• Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
• Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
• Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
• CV Events in Emetogenic Chemotherapy
• Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients
• Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist
• Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
• Venous Thromboembolism Prophylaxis Post Cesarean Section
• Ranibizumab and the Risk of Arterial Thromboembolic Events
• Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery
• Study Of Lybrel In Relation To Venous Thromboembolism
• PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
• The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
• BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery
• Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
• Dose-confirmatory Bridging Study in Total Knee Replacement
• Dose-confirmatory Bridging Study in Total Hip Replacement
• A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
• A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
• Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter
• Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
• A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
• Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
• A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
• Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
• Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
• Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
• Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
• Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
• Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
• The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
• An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
• Xarelto Regulatory Post-Marketing Surveillance
• YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
• Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)
• Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation
• Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
• Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism
• Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
• Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
• The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
• Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
• Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
• Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
• Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
• A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
• Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
• Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism
• Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
• Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
• Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
• A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
• D-Dimer Guided Oral Anticoagulant Treatment (OAT)
• Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.
• A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
• A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days
• Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
• Safety and Tolerability of Dabigatran Etexilate in Adolescents
• ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
• Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
• Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
• 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China
• Nadroparin for the Initial Treatment of Pulmonary Thromboembolism
• Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
• Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
• Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
• A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
• Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
• Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China
• Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
• Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
• Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
• Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
• Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
• Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
• Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
• Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage
• Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
• Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
• Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
• Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
• Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
• Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
• Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
• Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
• Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
• Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
• Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
• Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
• Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
• Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
• Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
• Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
• The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
• Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications
• Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
• A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
• Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
• Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
• Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
• A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
• Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
• Thromboprophylaxis and Bariatric Surgery
• Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
• Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis
• Thromboprophylaxis in Critically Ill Patients
• PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
• D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism
• Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
• Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
• An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
• Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
• Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
• Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
• Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
• A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Co
• Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
• Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
• Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
• Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
• Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
• Dose Ranging Study in Elective Total Hip Replacement Surgery
• Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients
• Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
• Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
• Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
• Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
• Secondary Prevention of Venous Thrombo Embolism (VTE).
• ARIXTRA Local Study For Registration In China.
• Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
• Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
• A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
• Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
• Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
• Enoxaparin in Acute Venous Thromboembolic Disease
• D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
• A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
• The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
• A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
• Odiparcil For The Prevention Of Venous Thromboembolism
• S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
• Aspirin for the Prevention of Recurrent Venous Thromboembolism
• CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
• Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
• Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin
• Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)
• Fixed Dose Heparin Study
• PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)
• PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
• Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
• RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
• Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
• Michelangelo - Oasis 5
• Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
• Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
• PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
• EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
• OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
• ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)
• A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased
• Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
• Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
• Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
• Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
• Heparin or Enoxaparin in Patients With Cancer
• Prevention of Recurrent Venous Thromboembolism (PREVENT)